bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

PDF file - 9585K, Supplementary Figure S3: (A) Representative FOXP3 stained TMA (x1.25). (B) Invasive carcinoma showing absence of FOXP3+ lymphocytes (x20). (C-D) Rare intratumoral FOXP3+ lymphocytes (<10) (x20, x40, respectively). (E-F) Intratumoral FOXP3+ lymphocytes (>10) (x20, x40, respectively). (G) Representative T-BET stained TMA (x1.25). (H) Invasive carcinoma showing absence of T-BET+ lymphocytes (x20). (I-J) Rare intratumoral T-BET+ lymphocytes (<10) (x20, x40, respectively). (K-L) Intratumoral T-BET+ lymphocytes (>10) (x20, x40, respectively).
Supplementary Figure 1 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

PDF file - 7284K, Supplementary Figure S1: (A) Representative CXCL10 stained TMA (x1.25). (B) Invasive carcinoma showing absence of tumoral CXCL10 expression (x20). (C) Low tumoral CXCL10 expression (x20). (D-E) Moderate and high tumoral CXCL10 expression (x20). (F) Representative CXCR3 stained TMA (x1.25). (G) Invasive carcinoma showing absence of tumoral CXCR3 expression. (H-I) Tumoral CXCR3 expression (x20).
Supplementary Methods from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Authors: O'Donnell Peter H. , Karovic Sanja , Karrison Theodore G. , Janisch Linda , Levine Matthew R. , Harris Pamela J. , Polite Blase N. , Cohen Ezra E.W. , Fleming Gini F. , Ratain Mark J. , Maitland Michael L.
Published: April 2023

Supplementary Methods from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Supplementary Table 1 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 21 KB, Real-time PCR primers used in this study.
Supplementary Figure 3 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
Authors: Fonte Eleonora , Apollonio Benedetta , Scarfò Lydia , Ranghetti Pamela , Fazi Claudia , Ghia Paolo , Caligaris-Cappio Federico , Muzio Marta
Published: April 2023

PDF file - 1885K, LT-alpha/TNF-beta protects CLL cells from drug-induced apoptosis
Supplementary Figure 6 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 3 MB, (A) The relative growth rates of T4597 tumors were determined as the weekly fold increases in bioluminescence intensity of individual tumors. Data shown were the mean � SEM (n=10). (B) The median bioluminescence intensities were generated from all 10 tumors in each arm. *: p< 0.05 by student's t-test.
Supplementary Figure 1 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
Authors: Fonte Eleonora , Apollonio Benedetta , Scarfò Lydia , Ranghetti Pamela , Fazi Claudia , Ghia Paolo , Caligaris-Cappio Federico , Muzio Marta
Published: April 2023

PDF file - 2581K, Stratification according to the underlying genetics
Supplementary Figure 5 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 1 MB, (A) T4302 CD133+ cells were infected with lentivirus directing expression of non-targeting (NT) shRNA or p53-specific shRNA. Downregulation of p53 was determined by immunoblotting 24 hours after JQ1 treatment. (B) Rb expression was determined by qRT-PCR in T4302 CD133+ cells expressing NT shRNA or Rb-specific shRNA. (C) Immunoblotting of Bcl-xL in T4302 CD133+ cells infected with control lentivirus or virus directing expression of Bcl-xL. (D) Immunoblotting of p21 in T4302 CD133+ cells expressing NT shRNA or p21-specific shRNA.
Supplementary Figure 2 from MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Authors: Wermke Martin , Schmidt Anne , Middeke Jan Moritz , Sockel Katja , von Bonin Malte , Schönefeldt Claudia , Mair Sabine , Plodeck Verena , Laniado Michael , Weiss Günter , Schetelig Johannes , Ehninger Gerhard , Theurl Igor , Bornhäuser Martin , Platzbecker Uwe
Published: April 2023

PDF file - 137K, Receiver-Operator-Characteristics of Transfusion Burden and Ferritin for the prediction of an LIC ≥ 125 �mol/g
Supplementary Figure 1 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 5 MB, (A) Dose-response curves of JQ1 in match CD133+ and CD133- cells enriched from the T4105 or T4597 primary glioblastoma xenograft lines. (B) Growth rates of T4302 CD133+ cells for 5 days were measured in the presence of JQ1 at indicated concentrations. (C) Dose-response curve of (-)-JQ1 in T4302 CD133+ cells. (D) Dose-response curve of PFI-1 in T4302 CD133+ cells. (E) T4302 CD133+ cells were treated by JQ1 for 72 hours at indicated concentrations.
Supplementary Table S2 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
Authors: Bjarnadottir Olöf , Kimbung Siker , Johansson Ida , Veerla Srinivas , Jönsson Mats , Bendahl Pär-Ola , Grabau Dorthe , Hedenfalk Ingrid , Borgquist Signe
Published: April 2023

Supplementary Table S2. Genes differential expressed between paired pre and post-statintreatment biopsies by two class SAM analyses. Only genes identified at an FDR=0 were considered as significant.
Supplementary Table S1 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
Authors: Bjarnadottir Olöf , Kimbung Siker , Johansson Ida , Veerla Srinivas , Jönsson Mats , Bendahl Pär-Ola , Grabau Dorthe , Hedenfalk Ingrid , Borgquist Signe
Published: April 2023

Supplementary Table S1. List of the gene-specific hydrolysis probes (Life Technologies) used for RT-qPCR.
Supplementary Table S5 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Table S5. Mutation summary in patients.
Supplementary Table S2 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Table S2. Sequence of primers for real-time PCR.
Supplementary Fig. S2 from Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Authors: Song Gina , Darr David B. , Santos Charlene M. , Ross Mark , Valdivia Alain , Jordan Jamie L. , Midkiff Bentley R. , Cohen Stephanie , Nikolaishvili-Feinberg Nana , Miller C. Ryan , Tarrant Teresa K. , Rogers Arlin B. , Dudley Andrew C. , Perou Charles M. , Zamboni William C.
Published: April 2023

Supplementary Fig. S2. The lumen analysis in representative vascularized areas in the T11 tumor
Supplementary Fig. S1 from Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Authors: Song Gina , Darr David B. , Santos Charlene M. , Ross Mark , Valdivia Alain , Jordan Jamie L. , Midkiff Bentley R. , Cohen Stephanie , Nikolaishvili-Feinberg Nana , Miller C. Ryan , Tarrant Teresa K. , Rogers Arlin B. , Dudley Andrew C. , Perou Charles M. , Zamboni William C.
Published: April 2023

Supplementary Fig. S1. Identification of subregions in the tumor for classification of F4/80-positive tumor-associated macrophages (TAM)
Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Authors: Lim Ho Yeong , Heo Jeong , Choi Hye Jin , Lin Cheng-Yao , Yoon Jung-Hwan , Hsu Chiun , Rau Kun-Ming , Poon Ronnie T.P. , Yeo Winnie , Park Joong-Won , Tay Miah Hiang , Hsieh Wen-Son , Kappeler Christian , Rajagopalan Prabhu , Krissel Heiko , Jeffers Michael , Yen Chia-Jui , Tak Won Young
Published: April 2023

Supplementary Figure 1. CONSORT diagram
Supplementary Figure Legends from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Legends for Supplementary Figures 1-6.
Data Supplement from Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Authors: Couraud Sébastien , Vaca-Paniagua Felipe , Villar Stéphanie , Oliver Javier , Schuster Tibor , Blanché Hélène , Girard Nicolas , Trédaniel Jean , Guilleminault Laurent , Gervais Radj , Prim Nathalie , Vincent Michel , Margery Jacques , Larivé Sébastien , Foucher Pascal , Duvert Bernard , Vallee Maxime , Le Calvez-Kelm Florence , McKay James , Missy Pascale , Morin Franck , Zalcman Gérard , Olivier Magali , Souquet Pierre-Jean
Published: April 2023

Supplemental Figure S1. Sample inclusion flow chart. Supplemental Figure S2. Boxplot of circulating free DNA concentration in plasma (in ng/microl) regarding M stage (up), and number of metastatic sites (down) in all samples (n=106). Y axis is in logarithmic scale. Supplemental Table S1. Processes used in the different participating labs for tumor DNA extraction, storage, shipment, and biomarker analysis. Supplemental Table S2. Primers used for amplicon sequencing by IonTorrent next-generation sequencing Supplemental Table S3. Multiplex reaction conditions. Supplemental Table S4. NGS mutation screening results in the 68 paired samples Supplemental Table S5. IonTorrent NGS test results in cfDNA, for each individual amplicon and overall, taking tDNA as a reference and restricted to stage IV samples (n=50). Supplemental Table S6. NGS test results in tDNA and cfDNA for all amplicons concomitantly using the ITVC strategy (5A), or the in-house strategy (5B); and corresponding calculated sensitivity for all matched samples analyzed by NGS (n=68)
Supplementary Tables 1 - 2, Figure 1 from Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro
Authors: Schenk Erin L. , Koh Brian D. , Flatten Karen S. , Peterson Kevin L. , Parry David , Hess Allan D. , Smith B. Douglas , Karp Judith E. , Karnitz Larry M. , Kaufmann Scott H.
Published: April 2023

PDF file, 105K, This file contains Supplemental Table 1 (Description of Patients Providing Samples for Assessment of Chk1 phosphorylation ), Supplemental Table 2 (Quantitative Effects of Cytarabine, SCH 900776 and the Combination on Samples from Patients in Cohort 2) and Supplemental Figure 1 (effects of SCH 900776 on cytarabine-induced killing in additional myeloid cell lines).
supplemental figure legend from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

supplemental figure legend
Supplementary figure 6 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 6: Comparison of FOXP3+ Treg frequencies between well differentiated cSCCs (G1) and moderately or poorly differentiated cSCCs (G2-3).
Supplementary figure 5 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 5: Tumoral Treg suppression of anti-CD3 induced tumoral effector T cell proliferation can be inhibited by anti-OX40.
Supplementary figure 1 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 1: Characterization of the cSCC immune infiltrate demonstrates the presence of tumoral Tregs.
Supplementary Table 5 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Table 5 - Summary of SNPs with p<0.0001 in AA patients with Grade 2-4 NE in E5103.
Supplementary Table 4 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Table 4 - Summary of SNPs with p<0.0001 in EA patients with Grade 2-4 NE in E5103.
Supplementary Figures 1 - 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Figure 1. Principal component analysis for patients in ECOG-5103 Supplementary Figure 2. Regional association (locuszoom) plots of rs3125923.
Supplementary Tables S1-S7 from Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
Authors: Ryner Lisa , Guan Yinghui , Firestein Ron , Xiao Yuanyuan , Choi Younjeong , Rabe Christina , Lu Shan , Fuentes Eloisa , Huw Ling-Yuh , Lackner Mark R. , Fu Ling , Amler Lukas C. , Bais Carlos , Wang Yulei
Published: April 2023

Supplementary Tables S1-S7. This is a multi-"tabbed" Excel file containing the supplementary data of the manuscript and includes a "Summary" tab with descriptions/captions for the enclosed data sheets. They are as follows: Supplementary Table S1: 800-gene Ovarian Cancer Biomarker Nanostring Panel content Supplementary Table S2: Fourteen differentially expressed genes between Plat-R primary vs Plat-S primary tumors (discovery dataset) Supplementary Table S3: Sixty five differentially expressed genes between Plat-R recurrent vs Plat-R primary tumors (discovery dataset) Supplementary Table S4: TP53 mutation status in 32 Plat-R and 26 Plat-S primary tumors (discovery dataset) Supplementary Table S5: CNV analysis on 35 cancer genes in 32 Plat-R and 26 Plat-S primary tumors (discovery dataset) Supplementary Table S6: Demographics summary of ICON7 chemo-treatment arm (biomarker population vs. ITT) Supplementary Table S7: Ten differentially expressed genes between Plat-R primary vs Plat-S primary tumors (ICON7 dataset)
Supplementary Data from Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation
Authors: Leisegang Matthias , Engels Boris , Schreiber Karin , Yew Poh Yin , Kiyotani Kazuma , Idel Christian , Arina Ainhoa , Duraiswamy Jaikumar , Weichselbaum Ralph R. , Uckert Wolfgang , Nakamura Yusuke , Schreiber Hans
Published: April 2023

Supplementary Methods - Contains detailed information on whole exome and RNA sequencing, variant calling, TCR gene transfer, and longitudinal imaging Supplementary Fig. S1 - Pipeline for exome/RNA analysis and neoepitope prediction Supplementary Fig. S2 - Pipeline for exome and clustering analysis of autochthonous 8101 tumor fragments Supplementary Fig. S3 - Generation of 1D9 T cells Supplementary Fig. S4 - Generation of mp68-expressing tumor cell lines Supplementary Fig. S5 - Expansion of 1D9 T cells is antigen-specific and not driven by lymphopenia-induced proliferation Supplementary Fig. S6 - 1D9 T cells do not infiltrate in tumors if mp68 is not expressed Supplementary Table S1 - Results of whole exome sequencing of Bulk tumor cells and Bulk reisolates after 1D9 T cell therapy Supplementary Table S2 - Results of whole exome sequencing of fragments derived from the autochthonous 8101 tumor
Supplementary Table 1 from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells
Authors: Gorges Tobias M. , Penkalla Nicole , Schalk Thomas , Joosse Simon A. , Riethdorf Sabine , Tucholski Johannes , Lücke Klaus , Wikman Harriet , Jackson Stephen , Brychta Nora , von Ahsen Oliver , Schumann Christian , Krahn Thomas , Pantel Klaus
Published: April 2023

Supplementary Table 1. Additional table showing summarized patient data correlated to the appearance of CTCs.
Supplemental Tables 1-4 from Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Authors: Wellbrock Jasmin , Latuske Emily , Köhler Julian , Wagner Katharina , Stamm Hauke , Vettorazzi Eik , Vohwinkel Gabi , Klokow Marianne , Uibeleisen Roswitha , Ehm Patrick , Riecken Kristoffer , Loges Sonja , Thol Felicitas , Schubert Claudia , Amling Michael , Jücker Manfred , Bokemeyer Carsten , Heuser Michael , Krauter Jürgen , Fiedler Walter
Published: April 2023

Supplemental Tables 1-4. Supplemental table S1: Primers used in RT-PCR; Supplemental table S2: PCR specificity and efficiency determined using plasmid standards; Supplemental table S3: Endpoint values of univariate analysis for event-free and overall survival for GLI1 expression in cohort B (n=290); Supplemental table S4: Gene expression in endothelial cell-enriched AML bone marrow.
Supplemental Figure 1 from Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Authors: Chapiro Julius , Sur Surojit , Savic Lynn Jeanette , Ganapathy-Kanniappan Shanmugasundaram , Reyes Juvenal , Duran Rafael , Thiruganasambandam Sivarajan Chettiar , Moats Cassandra Rae , Lin MingDe , Luo Weibo , Tran Phuoc T. , Herman Joseph M. , Semenza Gregg L. , Ewald Andrew J. , Vogelstein Bert , Geschwind Jean-François
Published: April 2023

This figure provides an overview of the TEM results.
Supplemental Figures 1-6 from Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Authors: Wellbrock Jasmin , Latuske Emily , Köhler Julian , Wagner Katharina , Stamm Hauke , Vettorazzi Eik , Vohwinkel Gabi , Klokow Marianne , Uibeleisen Roswitha , Ehm Patrick , Riecken Kristoffer , Loges Sonja , Thol Felicitas , Schubert Claudia , Amling Michael , Jücker Manfred , Bokemeyer Carsten , Heuser Michael , Krauter Jürgen , Fiedler Walter
Published: April 2023

Supplemental Figures 1-6. Supplemental figure S1: Semi-quantitative analysis of GLI2 expression in AML cohort A; Supplemental figure S2: Relative gene expression of Hedgehog family members in AML patient cohort A; Supplemental figure S3: Michael Friendly's fourfold displays for Hedgehog family members; Supplemental figure S4: Impact of GLI1 expression on clinical outcome in cohort B (n=290); Supplemental figure S5: Impact of GLI2 expression on clinical outcome in FLT3 subgroups of cohort B; Supplemental figure S6: BCL2 mRNA expression in GLI1/2 knockdown cells.
Supplemental Table 5 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Multivariable analysis corresponding to Figure 6C (iii)
Supplemental Table 4 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Multivariable analysis corresponding to Figures 6C (i) and (ii)
Supplemental Table 2 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Clinicopathologic characteristics of bladder cancer patient samples in microarray datasets
Supplementary Table S3 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S3. List of primers used for validation of WES findings in genes CARD11, CD79B, PRKCD and TNFAIP3. The same primers were used for PCR and Sanger sequencing reactions.
Supplementary Figures S1-S3 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Figures S1-S3. Supplementary Figure S1. Overview of copy number abnormalities identified in the cohort of PCNSL analyzed. Supplementary Figure S2. FISH screening of BCL6 break apart (A, left box), IGH-BCL6 fusion (A, right box), PRKCD (B) and TOX (C). Supplementary Figure S3. Univariate overall survival analysis based on the status of 6q21 (PRDM1).
Supplementary Appendix from Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors
Authors: Kryukov Gregory V. , Bielski Craig M. , Samocha Kaitlin , Fromer Menachem , Seepo Sara , Gentry Carleen , Neale Benjamin , Garraway Levi A. , Sweeney Christopher J. , Taplin Mary-Ellen , Van Allen Eliezer M.
Published: April 2023

This file contains additional details on the supplementary methods, plus supplementary tables and legends.
Supplementary Figure S1 from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Supplementary Figure S1. No effects on MMECs apoptosis and proliferation by the cMET inhibition.
Supplementary Tables 1-3, Figure Legends from A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: Small Eric J. , Lance Raymond S. , Gardner Thomas A. , Karsh Lawrence I. , Fong Lawrence , McCoy Candice , DeVries Todd , Sheikh Nadeem A. , GuhaThakurta Debraj , Chang Nancy , Redfern Charles H. , Shore Neal D.
Published: April 2023

Supplementary Tables 1-3, Figure Legends. ST1. Median cumulative product parameters, all randomized patients; ST2. Summary of maximal percent decrease from baseline in serum PSA; ST3: Most common AEs occurring within 1 day of infusion in >5% of patients.
Supplementary Figure 1 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Autophagic gene expression in human breast cancer. A. Autophagy genes significantly regulated in early versus never reoccurring breast cancers. B. Breast cancer survival in patients with high/low ATG7 and BECN1 expression.
Figure legends from Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Authors: Filatenkov Alexander , Baker Jeanette , Mueller Antonia M.S. , Kenkel Justin , Ahn G-One , Dutt Suparna , Zhang Nigel , Kohrt Holbrook , Jensen Kent , Dejbakhsh-Jones Sussan , Shizuru Judith A. , Negrin Robert N. , Engleman Edgar G. , Strober Samuel
Published: April 2023

Figure legends
Supplemental Figure 3 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Figure 3. Distribution of 3 subpopulations of monocytes in RCC patients.
Supplementary Table S2 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Clinical and pathological characteristics of ER+ advanced breast cancer patients treated or not with fulvestrant in the advanced disease setting.
Supplemental Figure Legends from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Authors: Brambilla Christian , Laffaire Julien , Lantuejoul Sylvie , Moro-Sibilot Denis , Mignotte Hélène , Arbib François , Toffart Anne-Claire , Petel Fabien , Hainaut Pierre , Rousseaux Sophie , Khochbin Saadi , de Reyniès Aurélien , Brambilla Elisabeth
Published: April 2023

Supplemental Figure Legends from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Supplemental data from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental data contains supplemental figure legends, supplemental tables and supplemental materials and methods. Supplemental Table 1. Target sequences of siRNAs Supplemental Table 2. Primer's sequences for RT-qPCR Supplemental Table S3: Patient characteristics
Supplemental Figures 1-8 from APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells
Authors: Cagnetta Antonia , Caffa Irene , Acharya Chirag , Soncini Debora , Acharya Prakrati , Adamia Sophia , Pierri Ivana , Bergamaschi Micaela , Garuti Anna , Fraternali Giulio , Mastracci Luca , Provenzani Alessandro , Zucal Chiara , Damonte Gianluca , Salis Annalisa , Montecucco Fabrizio , Patrone Franco , Ballestrero Alberto , Bruzzone Santina , Gobbi Marco , Nencioni Alessio , Cea Michele
Published: April 2023

Supplemental Figures 1-8. Figure 1S: A) Nampt locus (human chromosome 7q22.3) copy number heatmap for lines included in the Cancer Cell Line Encyclopedia. B) mRNA Nampt expression plotted vs. DNA copy number (log2 ratio). Figure 2S: effect of APO866 combined plus FK506 on Mec.1 cell lines. Figure 3S: intracellular APO866 determination in primary B-CLL cell extract. Figure 4S: anti-tumor activity of APO866 combined with Pg-p inhibitors (CsA, Verapamil and Nilotinib) on primary B-CLL and AML cells. Figure 5S: effects of drugs combination on healthy PBPCs (A) and PBMCs (B) cells. Figure 6S: intracellular NAD+(H) and ATP levels measured in AML cells following drugs combination. Figure 7S: relative expression of WBs showed in Figure 6B. Figure 8S: effects of NA addition on anti-tumor activity of APO866 combined with PgP inhibitors and schematic representation of proposed model.
Supplementary Table S3 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Statistical analysis of the correlation between FBW7 and TXNIP.
Supplementary Figure 4 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 85K, Supplementary figure 4. Killing of GD2+ Kelly by expanded gammadeltaT cells in the presence of ch14.18 (black) or anti-CD20 control antibody (grey).
Supplementary Figure 2 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 18K, Supplementary figure 2. Anti-gammadeltaTCR clone B1 is a murine IgG1.
Supplementary Figure 1 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 504K, Supplementary figure 1. Removal of CD14+/CD11c+ cells prior to gammadeltaTCR positive selection significantly increases sample purity.
Supplemental Tables from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Authors: Sterman Daniel H. , Alley Evan , Stevenson James P. , Friedberg Joseph , Metzger Susan , Recio Adri , Moon Edmund K. , Haas Andrew R. , Vachani Anil , Katz Sharyn I. , Sun Jing , Heitjan Daniel F. , Hwang Wei-Ting , Litzky Leslie , Yearley Jennifer H. , Tan Kay See , Papasavvas Emmanouil , Kennedy Paul , Montaner Luis J. , Cengel Keith A. , Simone Charles B. , Culligan Melissa , Langer Corey J. , Albelda Steven M.
Published: April 2023

Supplemental Tables 1-6 Supplemental Table 1. Results of some recent trials of chemotherapy in MPM. Supplemental Table 2. Post-Trial Therapies Supplemental Table 3. Characteristics of Patients Selected for Flow Cytometry Analysis Supplemental Table 4. List of Immune Response Genes assayed by Nanostring Supplemental Table 5: Correlation of Antibody Response to MOS or Radiographic Response Supplemental Table 6. Flow Cytometry Results
Supplementary Table 1 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Pathologic specifications of analyzed tumor specimens (formal pathologist review).
Supplementary table 8 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

A. Correlation of hypoxia gene-signatures and HPV16 DNA. B. Correlation of CSC marker expression and HPV16 DNA.
Supplementary table 5 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

Univariate analyses of CSC markers. HR = hazard ratio; 95% CI = 95 percent confidence interval.
Supplementary table 4 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

Correlation of tumor hypoxia using nanoString vs PCR.
Supplementary table 2 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

Univariate analyses of both hypoxia gene signatures using nanoString or RT-PCR analyses. HR = hazard ratio; 95% CI = 95 percent confidence interval.
Table S5 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

List of differentially secreted proteins between the EGF_cetuximab and EGF secretomes of SW48 parental cells in 3D
Supplementary table 1 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

A. Patient characteristics. B. Hypoxia gene signatures.
Supplemental table 2: Comparison of sensitivity of 18 DLBCL cell lines to ABT-199 and HHT. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

Cell of origin (COO), BCL2 expression status and IC100 for ABT-199 (Ã‚ÂµM) and HHT (nM) are shown.
supplemental figure legend from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

supplemental figure legend
Supplemental figure 6: Acquired resistance of DLBCL cells to HHT is associated with upregulation of BCL-XL protein. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

(A) Comparison of the extent of apopotosis induced by HHT (after 24hrs exposure) in HHT-resistant (HHT-R) clones compared to the original cell lines (CTRL). (B) Western blot analysis demonstrates upregulation of BCL-XL protein in HHT-R clones compared to CTRL cell lines.
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

Supplemental figure 4. IL6 and IL10 levels. Shown are data from five patients with elevated IL12 and IFNg levels that were subject to cytokine multiplex analysis. Only cytokine IL6 and IL10 were shown to be consistently elevated post-infusion.
Supplemental figure 1: Immunohistochemical (IHC) analysis of BCL2 and MCL1 proteins in formalin-fixed paraffin-embedded tissue samples obtained from patients at dignosis of DLBCL. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

Shown are examples of different levels of semi-quantitative protein expression (0-3).
Supplementary methods from Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Authors: Gao Huiping , Li Kesang , Tu Hong , Pan Xiaorong , Jiang Hua , Shi Bizhi , Kong Juan , Wang Hongyang , Yang Shengli , Gu Jianren , Li Zonghai
Published: April 2023

Supplementary methods
Supplementary figures 1-8 from Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Authors: Gao Huiping , Li Kesang , Tu Hong , Pan Xiaorong , Jiang Hua , Shi Bizhi , Kong Juan , Wang Hongyang , Yang Shengli , Gu Jianren , Li Zonghai
Published: April 2023

Supplementary figures 1-8. Supplementary Figure 1. The amino acid sequence of scFv GC33 in the construct of anti-GPC3 CAR. Supplementary Figure 2. The expression of CD64 and CD86 in the artificial antigen-presenting cell aK562-64/86. Supplementary Figure 3. Tumor outgrowth of Huh-7 cells was completely abolished by GPC3-targted CAR T cells in vivo. Supplementary Figure 4. Growth suppression on established s.c. HCC xenografts by GPC3-targeted CAR T cells. Supplementary Figure 5. Mice bearing orthotopic Huh-7 tumors. Supplementary Figure 6. The up-regulation of Bcl-XL protein in αGPC3-28BBZ CAR T cells was stimulated by GPC3-specific antigen. Supplementary Figure 7. The GPC3 expression in the normal kidney and gastric glands. Supplementary Figure 8. The homogeneity of GPC3 expression was analyzed in the human primary HCC tissues (n=75).
supplementary figure 3 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Authors: Napolitano Stefania , Martini Giulia , Rinaldi Barbara , Martinelli Erika , Donniacuo Maria , Berrino Liberato , Vitagliano Donata , Morgillo Floriana , Barra Giusy , De Palma Raffaele , Merolla Francesco , Ciardiello Fortunato , Troiani Teresa
Published: April 2023

supplementary figure 3. Pro-apoptotic effects of cetuximab in combination with regorafenib in SW620 CRC cell line with primary resistance to anti-EGFR inhibitor.
Supplemental Table 1 from First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Authors: Starodub Alexander N. , Ocean Allyson J. , Shah Manish A. , Guarino Michael J. , Picozzi Vincent J. , Vahdat Linda T. , Thomas Sajeve S. , Govindan Serengulam V. , Maliakal Pius P. , Wegener William A. , Hamburger Steven A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Serum concentration of intact sacituzumab govitecan and hRS7 IgG taken 30 min after injection for each of the 4 dose levels tested.
supplementary figure 1 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Authors: Napolitano Stefania , Martini Giulia , Rinaldi Barbara , Martinelli Erika , Donniacuo Maria , Berrino Liberato , Vitagliano Donata , Morgillo Floriana , Barra Giusy , De Palma Raffaele , Merolla Francesco , Ciardiello Fortunato , Troiani Teresa
Published: April 2023

supplementary figure 1. Effects of cetuximab in combination with regorafenib in a panel of CRC cell lines with primary and acquired resistance to anti-EGFR inhibitor in vitro.
Supplementary Figure 3 from A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases
Authors: Balachandran Vinod P. , Arora Arshi , Gönen Mithat , Ito Hiromichi , Turcotte Simon , Shia Jinru , Viale Agnes , Snoeren Nikol , van Hooff Sander R. , Rinkes Inne H.M. Borel , Adam René , Kingham T. Peter , Allen Peter J. , DeMatteo Ronald P. , Jarnagin William R. , D'Angelica Michael I.
Published: April 2023

mRNA expression and hierarchical clustering of molecular risk score (MRS) genes in colorectal liver metastases in derivation cohort. Genes are indicated on the x-axis, patients on the y-axis.
Supplementary Figure 2 from A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases
Authors: Balachandran Vinod P. , Arora Arshi , Gönen Mithat , Ito Hiromichi , Turcotte Simon , Shia Jinru , Viale Agnes , Snoeren Nikol , van Hooff Sander R. , Rinkes Inne H.M. Borel , Adam René , Kingham T. Peter , Allen Peter J. , DeMatteo Ronald P. , Jarnagin William R. , D'Angelica Michael I.
Published: April 2023

A. Overall survival in derivation (MSKCC) and validation (European) cohorts. B. Recurrence free survival in derivation (MSKCC) and validation (European) cohorts.
Supplementary Tables from Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Authors: Garner Andrew P. , Gozgit Joseph M. , Anjum Rana , Vodala Sadanand , Schrock Alexa , Zhou Tianjun , Serrano Cesar , Eilers Grant , Zhu Meijun , Ketzer Julia , Wardwell Scott , Ning Yaoyu , Song Youngchul , Kohlmann Anna , Wang Frank , Clackson Tim , Heinrich Michael C. , Fletcher Jonathan A. , Bauer Sebastian , Rivera Victor M.
Published: April 2023

Supplementary Tables. Table S1. In Vitro Kinase IC50 Values (nM) for Native and Mutant Recombinant KIT. Table S2. Summary of Ba/F3 KIT Cell Lines Generated in this Study. Table S3. Summary of IC50 Viability Values in Ba/F3 KIT Cells. Table S4. Summary of KIT Driven Ba/F3 In Vivo Studies.